nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2020-24-2-22-41nefr-1797Research ArticleСТРАНИЦА KDIGOKDIGO PAGEПринципы ведения гломерулярных болезней: итоги согласительной конференции Kidney disease: improving global outcomes (KDIGO). Часть 1Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conferenceФлёгеЮргенFloegeJűrgen

Подразделение Нефрологии и клинической Иммунологии

Пауэлсштрассе 30, 52057 Аахен

Division of Nephrology and Clinical Immunology

Pauwelsstrasse 30, 52057 Aachen

БарбоурШон Дж.BarbourSean J.

Отделение Нефрологии Университета Британской Колумбии

Центр оценки здоровья и результатов исследований Больницы Св. Павла

Ванкувер, Британская Колумбия

Division of Nephrology, University of British Columbia

Centre for Health Evaluation and Outcomes Research, St. Paul’s Hospital

Vancouver, British Columbia

КаттранДэниел К.CattranDaniel C.

Главный научно-исследовательский институт Торонто

Торонто, Онтарио

Toronto General Research Institute

Toronto, Ontario

ХоганДжонатан Дж.HoganJonathan J.

Отделение Нефрологии

Филадельфия, Пенсильвания

Division of Nephrology

Philadelphia, Pennsylvania

НачманПатрик Х.NachmanPatrick H.

Отделение болезней почек и гипертензии

Миннеаполис, Миннесота

Division of Renal Diseases and Hypertension

Minneapolis, Minnesota

ТангСидней С.В.TangSydney C.W.

Кафедра Медицины Университета Гонконга

Гонконг

Department of Medicine, The University of Hong Kong

Hong Kong

ВетцелсДжек Ф.М.WetzelsJack F.M.

Кафедра Нефрологии

Неймеген

Department of Nephrology

Nijmegen

ЧеунгМайклCheungMichael

Брюссель

Brussels

ВилерДэвид К.WheelerDavid C.

Лондон

London

ВинкелмайерВольфганг К.WinkelmayerWolfgang C.

Сельцманский институт здоровья почек, Секция Нефрологии, Кафедра медицины

Хьюстон, Техас

Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine

Houston, Texas

РовинБрэд Х.RovinBrad H.

Отделение Нефрологии, медицинский центр Уэкснер

12-я Вест-Авеню, 395, первый этаж, Колумбуя, Огайо 43210

Division of Nephrology, The Ohio State University, Wexner Medical Center

395 West 12th Avenue, Ground Floor, Columbus, Ohio 43210

rovin.1@osu.eduРейнско-Вестфальский технический университет г. АахенаГерманияRheinisch-Westfälische Technische Hochschule University of AachenGermanyРегиональное Почечное Агентство Британской Колумбии; Университет Британской Колумбии; Больница Св. ПавлаКанадаBritish Columbia Provincial Renal Agency; University of British Columbia; St. Paul’s HospitalCanadaУниверситетская сеть здравоохраненияКанадаUniversity Health NetworkCanadaУниверситет ПенсильванииСоединённые Штаты АмерикиUniversity of PennsylvaniaUnited StatesУниверситет МиннесотыСоединённые Штаты АмерикиUniversity of MinnesotaUnited StatesУниверситет Гонконга; Больница имени Королевы МарииКитайThe University of Hong Kong; Queen Mary HospitalChinaУниверситетский медицинский центр RadboudНидерландыRadboud University Medical CenterNetherlandsKDIGOБельгияKDIGOBelgiumУниверситетский колледж ЛондонаВеликобританияUniversity College LondonUnited KingdomМедицинский колледж БэйлорСоединённые Штаты АмерикиBaylor College of MedicineUnited StatesУниверситет штата ОгайоСоединённые Штаты АмерикиThe Ohio State UniversityUnited States2020070220202422241Copyright © Флёге Ю., Барбоур Ш., Каттран Д., Хоган Д., Начман П., Танг С., Ветцелс Д., Чеунг М., Вилер Д., Винкелмайер В., Ровин Б., 20202020Флёге Ю., Барбоур Ш., Каттран Д., Хоган Д., Начман П., Танг С., Ветцелс Д., Чеунг М., Вилер Д., Винкелмайер В., Ровин Б.Floege J., Barbour S., Cattran D., Hogan J., Nachman P., Tang S., Wetzels J., Cheung M., Wheeler D., Winkelmayer W., Rovin B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1797

По инициативе Kidney Disease: Improving Global Outcomes (KDIGO) в ноябре 2017 года была организована конференция по противоречивым вопросам в ведении гломерулярных болезней. Работа конференции была сфокусирована на рекомендациях KDIGO 2012 года и преследовала цель – определить новые моменты в понимании номенклатуры, патогенеза, диагностики и, в частности, лечения гломерулярной патологии. Участники пришли к консенсусу в том, что большинство основных рекомендаций, в особенности касающихся лечения, должны быть пересмотрены соответствующей рабочей группой. Данная часть отчета охватывает общие принципы ведения гломерулярных болезней, IgA-нефропатии и мембранозной нефропатии.

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline’s publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

гипертензияIgA-нефропатияKDIGOбиопсия почкимембранозная нефропатияпротеинурияhypertensionIgA nephropathyKDIGOkidney biopsymembranous nephropathyproteinuriaThe conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.ReferencesKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139–274. doi: 10.1038/kisup.2012.9Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139–274. doi: 10.1038/kisup.2012.9Sethi S, D’Agati VD, Nast CC et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int 2017;91:787–789. doi: 10.1016/j.kint.2017.01.002Sethi S, D’Agati VD, Nast CC et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int 2017;91:787–789. doi: 10.1016/j.kint.2017.01.002D’Agati VD, Mengel M. The rise of renal pathology in nephrology: structure illuminates function. Am J Kidney Dis 2013;61:10161025. doi: 10.1053/j.ajkd.2012.12.019D’Agati VD, Mengel M. The rise of renal pathology in nephrology: structure illuminates function. Am J Kidney Dis 2013;61:10161025. doi: 10.1053/j.ajkd.2012.12.019Larsen CP, Messias NC, Silva FG et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013;26:709–715. doi: 10.1038/modpathol.2012.207Larsen CP, Messias NC, Silva FG et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013;26:709–715. doi: 10.1038/modpathol.2012.207Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 2015;5:8803. doi: 10.1038/srep08803Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 2015;5:8803. doi: 10.1038/srep08803Hodgin JB, Bitzer M, Wickman L et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J Am Soc Nephrol 2015;26:3162–3178. doi: 10.1681/ASN.2014080752Hodgin JB, Bitzer M, Wickman L et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J Am Soc Nephrol 2015;26:3162–3178. doi: 10.1681/ASN.2014080752Beck LH Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543–1550. doi: 10.1681/ASN.2010111125Beck LH Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543–1550. doi: 10.1681/ASN.2010111125De Vriese AS, Glassock RJ, Nath KA et al. A proposal for a serologybased approach to membranous nephropathy. J Am Soc Nephrol 2017;28:421–430. doi: 10.1681/ASN.2016070776De Vriese AS, Glassock RJ, Nath KA et al. A proposal for a serologybased approach to membranous nephropathy. J Am Soc Nephrol 2017;28:421–430. doi: 10.1681/ASN.2016070776Sethi S, Glassock RJ, Fervenza FC. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 2015;30:375–384. doi: 10.1093/ndt/gfu035Sethi S, Glassock RJ, Fervenza FC. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 2015;30:375–384. doi: 10.1093/ndt/gfu035Hogan MC, Reich HN, Nelson PJ et al. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int 2016;90:1080–1089. doi: 10.1016/j.kint.2016.06.020Hogan MC, Reich HN, Nelson PJ et al. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int 2016;90:1080–1089. doi: 10.1016/j.kint.2016.06.020Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177–3183. doi: 10.1681/ASN.2007050526Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177–3183. doi: 10.1681/ASN.2007050526Lv J, Zhang H, Wong MG et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318:432–442. doi: 10.1001/jama.2017.9362Lv J, Zhang H, Wong MG et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318:432–442. doi: 10.1001/jama.2017.9362Hebert LA, Birmingham DJ, Shidham G et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract 2009;113:c177–c182. doi: 10.1159/000232599Hebert LA, Birmingham DJ, Shidham G et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract 2009;113:c177–c182. doi: 10.1159/000232599Rizk DV, Meier D, Sandoval RM et al. A novel method for rapid bedside measurement of GFR. J Am Soc Nephrol 2018;29:1609–1613. doi: 10.1681/ASN.2018020160Rizk DV, Meier D, Sandoval RM et al. A novel method for rapid bedside measurement of GFR. J Am Soc Nephrol 2018;29:1609–1613. doi: 10.1681/ASN.2018020160Ix JH, Wassel CL, Stevens LA et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol 2011;6:184–191. doi: 10.2215/CJN.05030610Ix JH, Wassel CL, Stevens LA et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol 2011;6:184–191. doi: 10.2215/CJN.05030610Gao A, Cachat F, Faouzi M et al. Comparison of the glomerular filtration rate in children by the new revised Schwartz formula and a new generalized formula. Kidney Int 2013;83:524–530Gao A, Cachat F, Faouzi M et al. Comparison of the glomerular filtration rate in children by the new revised Schwartz formula and a new generalized formula. Kidney Int 2013;83:524–530Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009;4: 1832–1843. doi: 10.2215/CJN.01640309Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009;4: 1832–1843. doi: 10.2215/CJN.01640309Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005;20:707–711. doi: 10.1093/ndt/gfh719Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005;20:707–711. doi: 10.1093/ndt/gfh719Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20:2305–2313. doi: 10.1681/ASN.2009020171Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20:2305–2313. doi: 10.1681/ASN.2009020171Inker LA, Tonelli M, Hemmelgarn BR, et al. Comparison of concurrent complications of CKD by 2 risk categorization systems. Am J Kidney Dis 2012;59:372–381. doi: 10.1053/j. ajkd.2011.09.021Inker LA, Tonelli M, Hemmelgarn BR, et al. Comparison of concurrent complications of CKD by 2 risk categorization systems. Am J Kidney Dis 2012;59:372–381. doi: 10.1053/j. ajkd.2011.09.021Tang LL, Liu A, Chen Z et al. Nonparametric ROC summary statistics for correlated diagnostic marker data. Stat Med 2013; 32:2209–2220. doi: 10.1002/sim.5654Tang LL, Liu A, Chen Z et al. Nonparametric ROC summary statistics for correlated diagnostic marker data. Stat Med 2013; 32:2209–2220. doi: 10.1002/sim.5654Geetha D, Seo P, Ellis C et al. Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy. J Rheumatol 2012;39:1413–1417. doi: 10.3899/jrheum.111608Geetha D, Seo P, Ellis C et al. Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy. J Rheumatol 2012;39:1413–1417. doi: 10.3899/jrheum.111608Sevillano AM, Gutierrez E, Yuste C et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 2017;28: 3089–3099. doi: 10.1681/ASN.2017010108Sevillano AM, Gutierrez E, Yuste C et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 2017;28: 3089–3099. doi: 10.1681/ASN.2017010108Levey AS, Inker LA, Matsushita K et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014;64:821–835. doi: 10.1053/j.ajkd.2014.07.030Levey AS, Inker LA, Matsushita K et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014;64:821–835. doi: 10.1053/j.ajkd.2014.07.030Thompson A, Cattran DC, Blank M et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015;26:2930–2937. doi: 10.1681/ASN.2015010091Thompson A, Cattran DC, Blank M et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015;26:2930–2937. doi: 10.1681/ASN.2015010091Cattran DC, Kim ED, Reich H et al. Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol 2017;28: 995–1003. doi: 10.1681/ASN.2015111262Cattran DC, Kim ED, Reich H et al. Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol 2017;28: 995–1003. doi: 10.1681/ASN.2015111262Morrell GR, Zhang JL, Lee VS. Magnetic resonance imaging of the fibrotic kidney. J Am Soc Nephrol 2017;28:2564–2570. doi: 10.1681/ASN.2016101089Morrell GR, Zhang JL, Lee VS. Magnetic resonance imaging of the fibrotic kidney. J Am Soc Nephrol 2017;28:2564–2570. doi: 10.1681/ASN.2016101089Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int 2001;59:1211–1226. doi: 10.1046/j.1523-1755.2001.0590041211.xHebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int 2001;59:1211–1226. doi: 10.1046/j.1523-1755.2001.0590041211.xBertram JF, Douglas-Denton RN, Diouf B et al. Human nephron number: implications for health and disease. Pediatr Nephrol 2011;26:1529–1533. doi: 10.1007/s00467-011-1843-8Bertram JF, Douglas-Denton RN, Diouf B et al. Human nephron number: implications for health and disease. Pediatr Nephrol 2011;26:1529–1533. doi: 10.1007/s00467-011-1843-8Ricardo AC, Goh V, Chen J et al. Association of sleep duration, symptoms, and disorders with mortality in adults with chronic kidney disease. Kidney Int Rep 2017;2:866–873. doi: 10.1016/j.ekir.2017.05.002Ricardo AC, Goh V, Chen J et al. Association of sleep duration, symptoms, and disorders with mortality in adults with chronic kidney disease. Kidney Int Rep 2017;2:866–873. doi: 10.1016/j.ekir.2017.05.002Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319–327. doi: 10.1053/ajkd.2003.50039Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319–327. doi: 10.1053/ajkd.2003.50039Afshinnia F, Wilt TJ, Duval S et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010;25:1173–1183. doi: 10.1093/ndt/gfp640Afshinnia F, Wilt TJ, Duval S et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010;25:1173–1183. doi: 10.1093/ndt/gfp640Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K et al. The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial. J Ren Nutr 2014;24:200–207. doi: 10.1053/j.jrn.2014.01.016Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K et al. The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial. J Ren Nutr 2014;24:200–207. doi: 10.1053/j.jrn.2014.01.016Cattran DC, Reich HN, Beanlands HJ et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23: 2247–2253. doi: 10.1093/ndt/gfm919Cattran DC, Reich HN, Beanlands HJ et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23: 2247–2253. doi: 10.1093/ndt/gfm919Sampson MG, Hodgin JB, Kretzler M. Defining nephrotic syndrome from an integrative genomics perspective. Pediatr Nephrol 2015;30:51–63Sampson MG, Hodgin JB, Kretzler M. Defining nephrotic syndrome from an integrative genomics perspective. Pediatr Nephrol 2015;30:51–63Preston R, Stuart HM, Lennon R. Genetic testing in steroidresistant nephrotic syndrome: why, who, when and how? Pediatr Nephrol 2019;34(2):195–210. doi: 10.1007/s00467-017-3838-6Preston R, Stuart HM, Lennon R. Genetic testing in steroidresistant nephrotic syndrome: why, who, when and how? Pediatr Nephrol 2019;34(2):195–210. doi: 10.1007/s00467-017-3838-6Agarwal R. Resistant hypertension and the neglected antihypertensive: sodium restriction. Nephrol Dial Transplant 2012;27:4041–4045. doi: 10.1093/ndt/gfs384Agarwal R. Resistant hypertension and the neglected antihypertensive: sodium restriction. Nephrol Dial Transplant 2012;27:4041–4045. doi: 10.1093/ndt/gfs384Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010;362:590–599. doi: 10.1056/NEJMoa0907355Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010;362:590–599. doi: 10.1056/NEJMoa0907355Voskamp PWM, Dekker FW, van Diepen M et al. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study. J Am Soc Hypertens 2017;11:635–643. doi: 10.1016/j.jash.2017.07.006Voskamp PWM, Dekker FW, van Diepen M et al. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study. J Am Soc Hypertens 2017;11:635–643. doi: 10.1016/j.jash.2017.07.006Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR et al. Aldosterone, renin, cardiovascular events, and all-cause mortality among African Americans: the Jackson Heart Study. JACC Heart Fail 2017;5:642–651. doi: 10.1016/j.jchf.2017.05.012Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR et al. Aldosterone, renin, cardiovascular events, and all-cause mortality among African Americans: the Jackson Heart Study. JACC Heart Fail 2017;5:642–651. doi: 10.1016/j.jchf.2017.05.012Petrykiv SI, Laverman GD, Persson F et al. Pooled analysis of multiple crossover trials to optimize individual therapy response to rennin-angiotensin-aldosterone system intervention. Clin J Am Soc Nephrol 2017;12:1804–1813. doi: 10.2215/CJN.00390117Petrykiv SI, Laverman GD, Persson F et al. Pooled analysis of multiple crossover trials to optimize individual therapy response to rennin-angiotensin-aldosterone system intervention. Clin J Am Soc Nephrol 2017;12:1804–1813. doi: 10.2215/CJN.00390117Antlanger M, Bernhofer S, Kovarik JJ et al. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in nondiabetic chronic kidney disease. Ann Med 2017;49:525–533. doi: 10.1080/07853890.2017.1313447Antlanger M, Bernhofer S, Kovarik JJ et al. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in nondiabetic chronic kidney disease. Ann Med 2017;49:525–533. doi: 10.1080/07853890.2017.1313447Rajasekeran H, Reich HN, Hladunewich MA et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined humanrodent pilot study. Am J Physiol Renal Physiol 2018;314:F412–F422. doi: 10.1152/ajprenal.00445.2017Rajasekeran H, Reich HN, Hladunewich MA et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined humanrodent pilot study. Am J Physiol Renal Physiol 2018;314:F412–F422. doi: 10.1152/ajprenal.00445.2017Markossian T, Burge N, Ling B et al. Controversies regarding lipid management and statin use for cardiovascular risk reduction in patients with CKD. Am J Kidney Dis 2016;67:965–977. doi: 10.1053/j.ajkd.2015.12.030Markossian T, Burge N, Ling B et al. Controversies regarding lipid management and statin use for cardiovascular risk reduction in patients with CKD. Am J Kidney Dis 2016;67:965–977. doi: 10.1053/j.ajkd.2015.12.030Lee T, Derebail VK, Kshirsagar AV et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int 2016;89:1111–1118. doi: 10.1016/j.kint.2015.12.041Lee T, Derebail VK, Kshirsagar AV et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int 2016;89:1111–1118. doi: 10.1016/j.kint.2015.12.041Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664Kotur-Stevuljevic J, Peco-Antic A, Spasic S et al. Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephrol 2013;28:295–303. doi: 10.1007/s00467-012-2323-5Kotur-Stevuljevic J, Peco-Antic A, Spasic S et al. Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephrol 2013;28:295–303. doi: 10.1007/s00467-012-2323-5Haynes R, Lewis D, Emberson J et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014;25:1825–1833. doi: 10.1681/ASN.2013090965Haynes R, Lewis D, Emberson J et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014;25:1825–1833. doi: 10.1681/ASN.2013090965Lee T, Biddle AK, Lionaki S et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 2014;85:1412–1420. doi: 10.1038/ki.2013.476Lee T, Biddle AK, Lionaki S et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 2014;85:1412–1420. doi: 10.1038/ki.2013.476Barbour SJ, Greenwald A, Djurdjev O et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012;81:190–195. doi: 10.1038/ki.2011.312Barbour SJ, Greenwald A, Djurdjev O et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012;81:190–195. doi: 10.1038/ki.2011.312Stamellou E, Floege J. Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 2018;33:1683–1689. doi: 10.1093/ndt/gfx322Stamellou E, Floege J. Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 2018;33:1683–1689. doi: 10.1093/ndt/gfx322Cholongitas E, Haidich AB, Apostolidou-Kiouti F et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol 2018;31:480–490. doi: 10.20524/aog.2018.0266Cholongitas E, Haidich AB, Apostolidou-Kiouti F et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol 2018;31:480–490. doi: 10.20524/aog.2018.0266National Renal Complement Therapeutics Centre. Guidelines for the prevention of meningococcal disease in adult patients receiving eculizumab for the treatment of atypical haemolytic uraemic syndrome. Available at: http://www.atypicalhus.co.uk/wp-content/uploads/2017/07/Meningococcal-guidelines-adult1.pdf. Accessed April 17, 2018National Renal Complement Therapeutics Centre. Guidelines for the prevention of meningococcal disease in adult patients receiving eculizumab for the treatment of atypical haemolytic uraemic syndrome. Available at: http://www.atypicalhus.co.uk/wp-content/uploads/2017/07/Meningococcal-guidelines-adult1.pdf. Accessed April 17, 2018Perkovic V, Agarwal R, Fioretto P et al. Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016;90:1175–1183. doi: 10.1016/j.kint.2016.09.010Perkovic V, Agarwal R, Fioretto P et al. Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016;90:1175–1183. doi: 10.1016/j.kint.2016.09.010Ayme S, Bockenhauer D, Day S et al. Common elements in rare kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017;92:796–808. doi: 10.1016/j.kint.2017.06.018Ayme S, Bockenhauer D, Day S et al. Common elements in rare kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017;92:796–808. doi: 10.1016/j.kint.2017.06.018Gadegbeku CA, Gipson DS, Holzman LB et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013;83:749–756. doi: 10.1038/ki.2012.428Gadegbeku CA, Gipson DS, Holzman LB et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013;83:749–756. doi: 10.1038/ki.2012.428Ju W, Nair V, Smith S et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 2015;7:316ra193. doi: 10.1126/scitranslmed.aac7071Ju W, Nair V, Smith S et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 2015;7:316ra193. doi: 10.1126/scitranslmed.aac7071Boyd JK, Cheung CK, Molyneux K et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012;81:833–843. doi: 10.1038/ki.2011.501Boyd JK, Cheung CK, Molyneux K et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012;81:833–843. doi: 10.1038/ki.2011.501Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 2018;33:763–777. doi: 10.1007/s00467-017-3699-zYeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 2018;33:763–777. doi: 10.1007/s00467-017-3699-zBerthoux F, Suzuki H, Thibaudin L et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;23:1579–1587. doi: 10.1681/ASN.2012010053Berthoux F, Suzuki H, Thibaudin L et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;23:1579–1587. doi: 10.1681/ASN.2012010053Yasutake J, Suzuki Y, Suzuki H et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 2015;30:1315-1321. doi: 10.1093/ndt/gfv221Yasutake J, Suzuki Y, Suzuki H et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 2015;30:1315-1321. doi: 10.1093/ndt/gfv221Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321–327. doi: 10.1038/ng.787Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321–327. doi: 10.1038/ng.787Fellstrom BC, Barratt J, Cook H et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a doubleblind, randomised, placebo-controlled phase 2b trial. Lancet 2017;389:2117–2127. doi: 10.1016/S01406736(17)30550-0Fellstrom BC, Barratt J, Cook H et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a doubleblind, randomised, placebo-controlled phase 2b trial. Lancet 2017;389:2117–2127. doi: 10.1016/S01406736(17)30550-0Suzuki H, Suzuki Y, Narita I et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008;19:23842395. doi: 10.1681/ASN.2007121311Suzuki H, Suzuki Y, Narita I et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008;19:23842395. doi: 10.1681/ASN.2007121311Niu D, Gao Y, Xie L et al. Genetic polymorphisms in TNFSF13 and FDX1 are associated with IgA nephropathy in the Han Chinese population. Hum Immunol 2015;76:831–835. doi: 10.1016/j.humimm.2015.09.044Niu D, Gao Y, Xie L et al. Genetic polymorphisms in TNFSF13 and FDX1 are associated with IgA nephropathy in the Han Chinese population. Hum Immunol 2015;76:831–835. doi: 10.1016/j.humimm.2015.09.044McCarthy DD, Kujawa J, Wilson C et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 2011;121:3991–4002. doi: 10.1172/JCI45563McCarthy DD, Kujawa J, Wilson C et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 2011;121:3991–4002. doi: 10.1172/JCI45563Maillard N, Wyatt RJ, Julian BA et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 2015;26:1503–1512. doi: 10.1681/ASN.2014101000Maillard N, Wyatt RJ, Julian BA et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 2015;26:1503–1512. doi: 10.1681/ASN.2014101000Xie J, Kiryluk K, Li Y et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol 2016;27:3187–3194. doi: 10.1681/ASN.2015111210Xie J, Kiryluk K, Li Y et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol 2016;27:3187–3194. doi: 10.1681/ASN.2015111210Rosenblad T, Rebetz J, Johansson M et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29: 2225–2228. doi: 10.1007/s00467-014-2863-yRosenblad T, Rebetz J, Johansson M et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29: 2225–2228. doi: 10.1007/s00467-014-2863-yRing T, Pedersen BB, Salkus G et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489–491. doi: 10.1093/ckj/sfv076Ring T, Pedersen BB, Salkus G et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489–491. doi: 10.1093/ckj/sfv076Block GA, Whitaker S. Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278. J Am Soc Nephrol 2017;28:749–750Block GA, Whitaker S. Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278. J Am Soc Nephrol 2017;28:749–750Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–545. doi: 10.1038/ki.2009.243Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–545. doi: 10.1038/ki.2009.243Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546–556. doi: 10.1038/ki.2009.168Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546–556. doi: 10.1038/ki.2009.168Coppo R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014;86:828–836. doi: 10.1038/ki.2014.63Coppo R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014;86:828–836. doi: 10.1038/ki.2014.63Barbour SJ, Espino-Hernandez G, Reich HN et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 2016;89:167–175. doi: 10.1038/ki.2015.322Barbour SJ, Espino-Hernandez G, Reich HN et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 2016;89:167–175. doi: 10.1038/ki.2015.322Haas M, Verhave JC, Liu ZH et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 2017;28:691–701. doi: 10.1681/ASN.2016040433Haas M, Verhave JC, Liu ZH et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 2017;28:691–701. doi: 10.1681/ASN.2016040433Tesar V, Troyanov S, Bellur S et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 2015;26:2248–2258. doi: 10.1681/ASN.2014070697Tesar V, Troyanov S, Bellur S et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 2015;26:2248–2258. doi: 10.1681/ASN.2014070697Herzenberg AM, Fogo AB, Reich HN et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011;80:310–317. doi: 10.1038/ki.2011.126Herzenberg AM, Fogo AB, Reich HN et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011;80:310–317. doi: 10.1038/ki.2011.126Espinosa M, Ortega R, Sanchez M et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014;9:897–904. doi: 10.2215/CJN.09710913Espinosa M, Ortega R, Sanchez M et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014;9:897–904. doi: 10.2215/CJN.09710913FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD; Bethesda, MD: US Food and Drug Administration; National Institutes of Health; 2016. Available at: https://www.ncbi.nlm.nih.gov/books/NBK326791/. Accessed May 1, 2018FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD; Bethesda, MD: US Food and Drug Administration; National Institutes of Health; 2016. Available at: https://www.ncbi.nlm.nih.gov/books/NBK326791/. Accessed May 1, 2018Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463Rauen T, Fitzner C, Eitner F et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol 2018;29:317–325. doi: 10.1681/ASN.2017060713Rauen T, Fitzner C, Eitner F et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol 2018;29:317–325. doi: 10.1681/ASN.2017060713Sarcina C, Tinelli C, Ferrario F et al. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 2016;11:973–981. doi: 10.2215/CJN.02300215Sarcina C, Tinelli C, Ferrario F et al. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 2016;11:973–981. doi: 10.2215/CJN.02300215Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebocontrolled randomized study. Kidney Int 2004;65:1842–1849. doi: 10.1111/j.1523-1755.2004.00588.xMaes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebocontrolled randomized study. Kidney Int 2004;65:1842–1849. doi: 10.1111/j.1523-1755.2004.00588.xFrisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139–2145. doi: 10.1093/ndt/gfh974Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139–2145. doi: 10.1093/ndt/gfh974Hogg RJ, Bay RC, Jennette JC et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 2015;66:783–791. doi: 10.1053/j.ajkd.2015.06.013Hogg RJ, Bay RC, Jennette JC et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 2015;66:783–791. doi: 10.1053/j.ajkd.2015.06.013Hou JH, Le WB, Chen N et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 2017;69:788–795. doi: 10.1053/j.ajkd.2016.11.027Hou JH, Le WB, Chen N et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 2017;69:788–795. doi: 10.1053/j.ajkd.2016.11.027Kawamura T, Yoshimura M, Miyazaki Y et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014;29:1546–1553. doi: 10.1093/ndt/gfu020Kawamura T, Yoshimura M, Miyazaki Y et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014;29:1546–1553. doi: 10.1093/ndt/gfu020Feehally J, Coppo R, Troyanov S et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy. Nephron 2016;132:15–24. doi: 10.1159/000441852Feehally J, Coppo R, Troyanov S et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy. Nephron 2016;132:15–24. doi: 10.1159/000441852Barbour SJ, Cattran DC, Kim SJ et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to endstage renal disease. Kidney Int 2013;84:1017–1024. doi: 10.1038/ki.2013.210Barbour SJ, Cattran DC, Kim SJ et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to endstage renal disease. Kidney Int 2013;84:1017–1024. doi: 10.1038/ki.2013.210Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110:434–437. doi: 10.1016/s0002-9343(01)00659-3Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110:434–437. doi: 10.1016/s0002-9343(01)00659-3Gutierrez E, Zamora I, Ballarin JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012;23:1753–1760. doi: 10.1681/ASN.2012010063Gutierrez E, Zamora I, Ballarin JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012;23:1753–1760. doi: 10.1681/ASN.2012010063Tang SC, Tang AW, Wong SS et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543–549. doi: 10.1038/ki.2009.499Tang SC, Tang AW, Wong SS et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543–549. doi: 10.1038/ki.2009.499Lafayette RA, Canetta PA, Rovin BH et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 2017;28:1306–1313. doi: 10.1681/ASN.2016060640Lafayette RA, Canetta PA, Rovin BH et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 2017;28:1306–1313. doi: 10.1681/ASN.2016060640Yu MY, Kim YC, Chin HJ. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of glomerular filtration rate during 5 yearfollow up period in IgA nephropathy. Abstract SA-PO272. J Am Soc Nephrol 2017;28:748Yu MY, Kim YC, Chin HJ. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of glomerular filtration rate during 5 yearfollow up period in IgA nephropathy. Abstract SA-PO272. J Am Soc Nephrol 2017;28:748Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11–21. doi: 10.1056/NEJMoa0810457Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11–21. doi: 10.1056/NEJMoa0810457Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371:2277–2287. doi: 10.1056/NEJMoa1409354Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371:2277–2287. doi: 10.1056/NEJMoa1409354Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLADQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364:616–626. doi: 10.1056/NEJMoa1009742Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLADQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364:616–626. doi: 10.1056/NEJMoa1009742Cui Z, Xie LJ, Chen FJ et al. MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy. J Am Soc Nephrol 2017;28:1651–1664. doi: 10.1681/ASN.2016020114Cui Z, Xie LJ, Chen FJ et al. MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy. J Am Soc Nephrol 2017;28:1651–1664. doi: 10.1681/ASN.2016020114Du Y, Li J, He F et al. The diagnosis accuracy of PLA2RAB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS One 2014;9:e104936. doi: 10.1371/journal.pone.0104936Du Y, Li J, He F et al. The diagnosis accuracy of PLA2RAB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS One 2014;9:e104936. doi: 10.1371/journal.pone.0104936Dahan K, Debiec H, Plaisier E et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 2017;28:348–358. doi: 10.1681/ASN.2016040449Dahan K, Debiec H, Plaisier E et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 2017;28:348–358. doi: 10.1681/ASN.2016040449Hofstra JM, Wetzels JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol 2014;25:1137–1139. doi: 10.1681/ASN.2014010091Hofstra JM, Wetzels JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol 2014;25:1137–1139. doi: 10.1681/ASN.2014010091Seitz-Polski B, Debiec H, Rousseau A et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J Am Soc Nephrol 2018;29:401–408. doi: 10.1681/ASN.2017070734Seitz-Polski B, Debiec H, Rousseau A et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J Am Soc Nephrol 2018;29:401–408. doi: 10.1681/ASN.2017070734Radice A, Trezzi B, Maggiore U et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 2016;15:146–154. doi: 10.1016/j.autrev.2015.10.004Radice A, Trezzi B, Maggiore U et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 2016;15:146–154. doi: 10.1016/j.autrev.2015.10.004Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 2013;9:443–458. doi: 10.1038/nrneph.2013.125Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 2013;9:443–458. doi: 10.1038/nrneph.2013.125van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol 2016;9:1463–1478. doi: 10.1080/17512433.2016.1225497van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol 2016;9:1463–1478. doi: 10.1080/17512433.2016.1225497Ramachandran R, Hn HK, Kumar V et al. Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology 2016;21:139–146. doi: 10.1111/nep.12569Ramachandran R, Hn HK, Kumar V et al. Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology 2016;21:139–146. doi: 10.1111/nep.12569Qiu TT, Zhang C, Zhao HW et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoim-mun Rev 2017;16:136–145. doi: 10.1016/j.autrev.2016.12.005Qiu TT, Zhang C, Zhao HW et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoim-mun Rev 2017;16:136–145. doi: 10.1016/j.autrev.2016.12.005Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013;381:744–751. doi: 10.1016/S0140-6736(12)61566-9Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013;381:744–751. doi: 10.1016/S0140-6736(12)61566-9van den Brand J, Ruggenenti P, Chianca A et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 2017;28:2729–2737. doi: 10.1681/ASN.2016091022van den Brand J, Ruggenenti P, Chianca A et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 2017;28:2729–2737. doi: 10.1681/ASN.2016091022Ruggenenti P, Debiec H, Ruggiero B et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2015;26:2545–2558. doi: 10.1681/ASN.2014070640Ruggenenti P, Debiec H, Ruggiero B et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2015;26:2545–2558. doi: 10.1681/ASN.2014070640Hofstra JM, Debiec H, Short CD et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1735–1743. doi: 10.1681/ASN.2012030242Hofstra JM, Debiec H, Short CD et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1735–1743. doi: 10.1681/ASN.2012030242

The authors declare that there are no conflicts of interest present.